White Gold Corp. Encounters Gold in Encouraging Host Rocks of Altered and Mineralized Intrusives in Surface Rock Sampling over 1.25km on the Newly Discovered 2.2km Chris Creek Target on the QV Property

Sep 26, 2024

TORONTO, Sept. 26, 2024 – White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the “Company”) is pleased to announce that surface rock sampling has encountered gold with associated anomalous silver and tellurium in altered and mineralized intrusive rocks over...

Fireweed Grows Boundary Zone, Intersecting 92.15 m of 8.61% Zinc, 2.60% Lead, and 42.7 g/t Silver, Including 11.21 m of 21.40% Zinc, 6.66% Lead, and 107.6 g/t Silver at the Macpass Project

Sep 26, 2024

VANCOUVER, British Columbia, Sept. 26, 2024 – FIREWEED METALS CORP. (“Fireweed” or the “Company”) (TSXV: FWZ; OTCQX: FWEDF) is pleased to report the initial results of the 2024 drill campaign, announce the appointment of Graham Richardson as the Company’s CFO,...

Anfield Commences Drill Program at Slick Rock

Sep 24, 2024

VANCOUVER, British Columbia, Sept. 24, 2024 – Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to announce that it has commenced a 20-hole, 20,000-foot rotary drill program at its Slick Rock uranium and...

PharmaDrug’s Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

Sep 19, 2024

Toronto, Ontario – September 19, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

Sep 18, 2024

TORONTO, Sept. 18, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

PharmaDrug’s Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

Aug 28, 2024

Toronto, Ontario – August 28, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances...